Physiologic Change of Posterior Ocular Segment During Pregnancy

NCT ID: NCT04731415

Last Updated: 2021-06-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

69 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-07-01

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Women's physiology changes markedly during normal pregnancy. The most distinct alterations occur in the hormonal and cardiovascular systems. There is a dramatic increase in both estrogen and progesterone. Blood volume starts to increase in the first gestational period and reaches a peak in the third trimester.

The physiologic ocular changes during pregnancy are mainly the result of hormonal and blood volume increase, and then are usually marked in the third trimester.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Ocular anterior segment changes during pregnancy are the followings

* Melanogenesis of eyelid and facial skin -\> melasma
* Cellular alteration of lacrimal and meibomian gland -\> dry eye symptoms
* Increased corneal thickness and corneal curvature -\> contact lens intolerance
* Increased lens thickness -\> loss of accommodation
* Decreased intraocular pressure -\> better glaucoma control There are few studies of posterior changes in pregnant women. Many limitations of previous publications includes lack of internal control and no data of postpartum contraception. However, choroidal thickness seems to be thicker in pregnant women than non-pregnant women. The other changes are non-inclusive.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retinal Vascular

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy pregnant women

Optical coherence tomography and Optical coherence tomography angiography using Optovue® were performed in each trimester and at 6 weeks after childbirth.

Group Type OTHER

Optical coherence tomography and optical coherence tomography angiography (Optovue®)

Intervention Type DEVICE

Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.

1. st trimester : gestational age 8-12 weeks
2. nd trimester : gestational age 24-28 weeks
3. rd trimester : gestational age 34-38 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Optical coherence tomography and optical coherence tomography angiography (Optovue®)

Optical coherence tomography and optical coherence tomography angiography (Optovue®) were performed in each trimesters and at 6 weeks after childbirth.

1. st trimester : gestational age 8-12 weeks
2. nd trimester : gestational age 24-28 weeks
3. rd trimester : gestational age 34-38 weeks

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy pregnant women
* Age \> 18 years
* Gestational age \< 12 weeks
* Written informed consent

Exclusion Criteria

* High risk pregnancy such as multifetal pregnancy and preeclampsia
* History of vitreoretinal diseases such as retinal vasculitis
* History of intraocular laser treatments or intraocular surgeries
* History of systemic diseases such as diabetes mellitus and thyroid disease
* Refractive error; spherical equivalence \> 4 diopters
* Clear ocular media
* Could not be taken the images by non-dilated pupil

Withdrawal Criteria:

* Preterm labor; gestational age \< 34 weeks
* Multifetal pregnancy was demonstrated by ultrasound
* Severe labor and delivery complications such as
* Severe postpartum complications such as postpartum bleeding
* Taking hormone during the follow-up period
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Khon Kaen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Suthasinee Sinawat

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Suthasinee Sinawat, MD

Role: PRINCIPAL_INVESTIGATOR

KKU Eye Center, Department of Ophthalmology, Faculty of Medicine, Khon Kaen University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Khon Kaen University

Khon Kaen, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Suthasinee Sinawat, MD

Role: CONTACT

+66 81 5454594

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HE631577

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Retinal Investigation Using Optos OCT Device
NCT06846151 NOT_YET_RECRUITING NA